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TatHIV transcription is regulated at the step of elongation by the viral Tat protein and the cellular positive tran-
scription elongation factor b (P-TEFb; Cdk9/cyclin T1). Herein, a human cyclin T1 mutant, cyclin T1-U7, which
contains four substitutions and one deletion in the N-terminal cyclin box, was stably expressed in HeLa cells.
HIV transcription was efﬁciently inhibited in HeLa–HA-CycT1-U7 stable cells. Cyclin T1-U7 bound Tat but did
not modulate its expression levels, which remained high. Importantly cyclin T1-U7 failed to interact with
Cdk9 or HEXIM1 and did not interfere with endogenous P-TEFb activity to stimulate MEF2C or NFkB mediat-
ed transcription. In a T cell line and primary CD4+ cells, cyclin T1-U7 also inhibited HIV transcription. We
conclude that cyclin T1-U7 sequesters Tat from P-TEFb and inhibits HIV transcription. Importantly,
N-terminal residues in cyclin T1 are speciﬁcally involved in the binding of cyclin T1 to HEXIM1 but not to Tat.
© 2012 Elsevier Inc. All rights reserved.Introduction
Since its discovery Human Immunodeﬁciency Virus type 1
(HIV-1), the causative agent of AIDS, has led to the death of close to
25 million people worldwide. Despite the availability of effective
anti-HIV drugs, rapid emergence of drug resistant variants hampers
the development of new therapeutic approaches. Moreover an efﬁ-
cient vaccine is currently not available (Ho and Bieniasz, 2008).
HIV replication is regulated at the step of transcription elongation
by the viral Tat protein and cellular cofactors (Ott et al., 2011; Peterlin
and Price, 2006). A recent development of genome wide gene expres-
sion analysis and bioinformatics indicates that most of cellular gene
expression is also regulated at the elongation step in a manner similar
to HIV transcription (Fuda et al., 2009; Hah et al., 2011). As such, HIV
has become a model for studying transcriptional elongation in eu-
karyotes. In HIV, the viral protein Tat binds the host cyclin T1
(CycT1) and recruits the positive transcription elongation factor b
(P-TEFb) to the viral promoter. P-TEFb assembles on the transactiva-
tion response RNA element (TAR), leading to hyper-phosphorylation
of the C-terminal domain (CTD) of RNA Polymerase II (RNAPII) byand Developmental Genetics,
he Negev, P.O. Box 653. Beer-
rights reserved.Cdk9. This step releases RNAPII from its pause and signiﬁes the tran-
sition from initiation to elongation of viral transcription (Barboric and
Peterlin, 2005; Peterlin and Price, 2006; Wei et al., 1998; Zhou and
Yik, 2006). In cells, there is equilibrium between transcriptionally ac-
tive and inactive P-TEFb. Active P-TEFb consists of Cdk9 and either cy-
clin T1, T2a or T2b, while inactive complex comprises of Cdk9, cyclin
T, 7SK small nuclear RNA (snRNA) and hexamethylene bisacetamide-
inducible protein 1 (HEXIM1) (Nguyen et al., 2001; Yang et al., 2001).
C-terminal residues in HEXIM1 mediate binding to CycT1, while Tat-
TAR recognition motif (TRM) in the cyclin box of CycT1 is important
for the interactions with HEXIM1 (Michels et al., 2003, 2004;
Schulte et al., 2005; Yik et al., 2003, 2004). TRM also mediates binding
of CycT1 to Tat (Garber et al., 1998) and was recently reported to
form a hydrophobic pocket with additional N-terminal residues in
CycT1 to mediate binding to Tat and promote Tat transactivation
(Asamitsu et al., 2011). Overall, Tat and HEXIM1 compete for the
binding of CycT1 (Schulte et al., 2005).
As P-TEFb is essential for HIV replication, it serves as a potential
target for anti-HIV therapeutics. However, since P-TEFb is involved
in the transcription of numerous cellular genes, it is critical to exclu-
sively block HIV-speciﬁc transcription (Barboric et al., 2001; Gargano
et al., 2007; Kanazawa et al., 2000; Simone et al., 2002a, 2002b; Yik et
al., 2005). Several approaches have been taken to inhibit HIV tran-
scription by targeting P-TEFb. Small compounds that inhibit Cdk9 ki-
nase activity, kinase defective Cdk9 and chimeric proteins consisting
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et al., 2002; Hwang et al., 2003; Lind et al., 2002; Mischiati et al.,
2001; Napolitano et al., 2003; Richter and Palu, 2006). CycT1 mutants
displaying dominant negative activity were also developed based on
the structure of CycT1. (Anand et al., 2007, 2008; Baumli et al.,
2008; Tahirov et al., 2010). However, the efﬁciency of these mutants
was poor when tested in vivo. Of interest, one CycT1 mutant,
CycT1-U7, consists of the ﬁrst 280 residues of CycT1 and also contains
four substitutions and one deletion in the second helix H2 of the N-
terminal cyclin box region (residues HRFYM to IIWE at positions
67–71). CycT1-U7 was recently reported to inhibit Tat transactivation
in-vitro due to its low expression, also leading to Tat degradation
(Jadlowsky et al., 2008).
Herein cyclin T1-U7 was further characterized for interactions
with Cdk9 and HEXIM1, as well as with Tat, and its effects on HIV
transcription were evaluated. When stably expressed in cells, cyclin
T1-U7 efﬁciently inhibited HIV transcription, without modulating
Tat expression levels. Cyclin T1-U7 bound Tat, but failed to interact
with Cdk9 or HEXIM1, implying that N-terminal residues in the cyclin
box of CycT1 are important for binding to both Cdk9 and HEXIM1.
Moreover, CycT1-U7 had no toxic effects on cells, and also did not in-
terfere with endogenous P-TEFb activity to stimulate previouslyFig. 1. Stable expression of HA-CycT1-U7 in cells(A) Model Structure of P-TEFb (Cdk9/cyclin
(Cdk9/CycT1) structure, where cyclin T1-U7 mutations are highlighted. Cyclin T1-U7 consi
were inserted. HRFYM residues at position 67–71 are mutated to IIWE. Mutations are posi
of Cdk9. They form a hydrophobic pocket that may be disrupted and confer changes in
2008).(B) Schematic representation of the lentivector expressing HA-CycT1-U7 — HA-CycT
under the CMV promoter. The lentivector also contained an IRES sequence for the express
expression of packaging HIV plasmids and VSV-G envelope. Supernatant containing HA-
HeLa cells. 48 h post transduction virus was removed and HeLa cells were subjected to puro
ilarly generated with lentivirus that did not express HA-CycT1-U7.(C) Stable expression of H
and western blot analysis with an anti-HA monoclonal antibody (lane 3). Control HeLa cell
β-actin were also monitored to conﬁrm equal amounts of protein that were loaded on the g
levels of HIV-1 Tat — Control cells that did not express HA-CycT1-U7 (lane 1) or HeLa–HA-
fectamine 2000 (Invitrogen). 48 h post transfection cells were lysed and subjected to SDS-PA
were transfected with HA-pCDNA3 empty vector (lane 2). Expression levels of β-actin we
panel).reported P-TEFb dependent promoters like myocyte enhancer
factor-2 (MEF2C) or NFkB dependent transcription (Barboric et al.,
2001; Nojima et al., 2008). In a T cell line and primary CD4+ cells, cy-
clin T1-U7 inhibited HIV gene transcription. We conclude that cyclin
T1-U7 inhibits HIV gene transcription by sequestering Tat from P-
TEFb. Importantly, N-terminal residues in cyclin T1 are speciﬁcally in-
volved in the binding of cyclin T1 to HEXIM1 but not to Tat.
Results
Stable expression of cyclin T1-U7 in cells
The cyclin T1 (CycT1) mutant, CycT1-U7, consists of the ﬁrst 280
residues of human CycT1, with four substitutions and one deletion
in the second helix, H2, of the N-terminal cyclin box (residues
HRFYM to IIWE at positions 67–71). Fig. 1A presents the structure
of P-TEFb (Cdk9/CycT1), where N-terminal residues that are mutated
in CycT1-U7 are highlighted (Baumli et al., 2008). Mutated CycT1-U7
residues are located in close proximity to the N-terminus of Cdk9.
They are part of a hydrophobic pocket that may be disrupted and con-
fer changes in the structure of cyclin T1, thus affecting binding of cy-
clin T1 to Cdk9 (Fig. 1A).T1) with highlighted residues that are mutated in CycT1-U7 — Presented is the P-TEFb
sts of N-terminal 280 residues of cyclin T1, where four substitutions and one deletion
tioned in the N-terminal cyclin box of cyclin T1, in close proximity to the N-terminus
the structure of cyclin T1 that affects binding to Cdk9 and HEXIM1 (Baumli et al.,
1-U7 was cloned into a lentiviral expression plasmid and its expression was regulated
ion of puromycin selection gene. Lentiviruses were generated in HEK293T cells by co-
CycT1-U7 lentivirus was collected 48 h post transfection and was used to transduce
mycin selection to obtain HeLa–HA-CycT1-U7 stable cells. Control HeLa cells were sim-
A-CycT1-U7 — HeLa–HA-CycT1-U7 stable cells were lysed and subjected to SDS-PAGE
s that did not express HA-CycT1-U7 were used as control (lane 2). Expression levels of
el (lower panel).(D) Stably expressed HA-CycT1-U7 does not modulate the expression
CycT1-U7 stable cells (lane 3) were transfected with HIV-1 HA-Tat plasmid using lipo-
GE and western blot analysis with an anti-HA antibody. As a negative control, HeLa cells
re monitored to verify equal amounts of proteins that were loaded on the gel (lower
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levels when transiently expressed, but efﬁciently inhibits Tat transac-
tivation by promoting HIV Tat degradation. However, despite elevat-
ed levels of CycT1-U7 and Tat following treatment of cells with
protease inhibitors, Tat transactivation was not fully restored
(Jadlowsky et al., 2008), which suggested that there exist additional
pathways for CycT1-U7-mediated inhibition of Tat transactivation
and HIV transcription. To further characterize the inhibitory mecha-
nism of CycT1-U7 on HIV transcription in cells, HA-CycT1-U7 was sta-
bly expressed in cells. HeLa cells were transduced with lentivirus that
expressed HA-CycT1-U7 under the regulation of the CMV promoter,
generating the cell line — HeLa–HA-CycT1-U7. The lentivector also
coded for a puromycin resistant marker to allow selection for HA-
CycT1-U7 expressing stable cells (Fig. 1B). Western blot analysis
using anti-HA antibody conﬁrmed high HA-CycT1-U7 expression in
HeLa–HA-CycT1-U7 stable cells, as compared with control HeLa cells
that were transduced with an empty lentivector, thus did not express
HA-CycT1-U7 (Fig. 1C; compare lanes 2 and 3). Since it was previous-
ly reported that low expression levels of CycT1-U7 facilitate Tat deg-
radation, HeLa–HA-CycT1-U7 stable cells and control HeLa cells were
transfected with an expression plasmid that coded HA-Tat. Expres-
sion levels of HA-Tat in HeLa–HA-CycT1-U7 stable cells were moni-
tored by western blotting and compared with Tat expression levels
in cells that did not express HA-CycT1-U7 (Fig. 1D). In HeLa–HA-
CycT1-U7 stable cells, expression levels of Tat were not down modu-
lated and were similar to those detected in control HeLa cells that didFig. 2. Stably expressed HA-CycT1-U7 inhibits LTR-Tat-dependent lentiviral transcription(A
lentivirus — HeLa–HA-CycT1-U7 (white bars) or cells that did not express HA-CycT1-U7 (b
BFP lentivirus, where BFP expression was regulated under the control of the HIV-LTR prom
FACS. Panel (A) represents geomean values and panel (B) shows percentage of cells that we
tion efﬁciencies in both cell types. Data are the representative of three independent expe
CycT1-U7 stable cells (gray line) or HeLa control cells that did not express HA-CycT1-U7
Cells were harvested 48 h post transduction and analyzed by FACS for BFP expression. Si
expressed HA-CycT1-U7 does not inhibit gene transcription of an HIV-CMV-BFP lentiviru
HA-CycT1-U7 (black bars) were transduced with decreasing MOI of VSV-G pseudotyped H
CMV promoter. 48 h post transduction, cells were harvested and analyzed for BFP express
the representative of three independent experiments and error bars represent standard denot express HA-CycT1-U7 (Fig. 1D; compare lanes 3 and 1, respective-
ly). As control, HeLa cells were also transfected with an empty HA-
pCDNA3 plasmid (lane 2). Western blot analysis for the expression
of β-actin conﬁrmed equal protein levels in all samples that were
loaded on the gel (Fig. 1D; lower panel). Overall, these results demon-
strated that HA-CycT1-U7 was efﬁciently expressed in stable cells and
did not modulate the expression of Tat.
Stably expressed HA-CycT1-U7 inhibits HIV gene transcription
To test if stably-expressed HA-CycT1-U7 speciﬁcally inhibits HIV
gene transcription, HeLa–HA-CycT1-U7 stable cells were transduced
with VSV-G pseudotyped HIV that expressed the Blue Fluorescent
Protein (BFP) reporter gene under the regulation of the HIV-LTR pro-
moter and of Tat, which was expressed in cis (Tyagi et al., 2010). As a
control, HeLa cells that did not express HA-CycT1-U7 were also trans-
duced with a VSV-G pseudotyped LTR-Tat-BFP lentivirus (Fig. 2). Viral
titer was determined by analysis of BFP expression following trans-
duction of 293 T cells and was calculated as 1×107/ml (see
Materials andmethods). As shown, at different viral multiplicity of in-
fection (MOI), gene transcription of the HIV-LTR-BFP lentivirus was
efﬁciently inhibited in HeLa–HA-CycT1-U7 stable cells (Fig. 2A;
white bars). In control cells that did not express HA-CycT1-U7, tran-
scription of HIV-LTR-Tat-BFP lentivirus was not inhibited (Fig. 2A;
black bars). Signiﬁcantly, inhibition of viral transcription was
detected only in geomean values of transduction (Fig. 2A), while, B) Stably expressed HA-CycT1-U7 inhibits gene transcription of an HIV-LTR-Tat-BFP
lack bars) were transduced with decreasing MOI of VSV-G pseudotyped HIV-LTR-Tat-
oter. 48 h post transduction, cells were harvested and analyzed for BFP expression by
re infected by the lentivirus and expressed BFP, conﬁrming high and similar transduc-
riments and error bars represent standard deviation.(C) FACS histogram of HeLa–HA-
(black line), which were transduced with HIV-LTR-Tat-BFP lentivirus at an MOI of 4.
milar plots were obtained following transduction of cells at different MOI.(D) Stably
s — HeLa–HA-CycT1-U7 cells (white bars) or control HeLa cells that did not express
IV-CMV-BFP lentiviruses, where BFP expression was regulated under a control of the
ion by FACS. Presented are geomean values obtained from the FACS analysis. Data are
viation.
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expressed BFP were similar in both HeLa–HA-CycT1-U7 stable cells
or control cells (Fig. 2B). This conﬁrmed that the inhibitory effects
of HA-CycT1-U7 were measured only on the intensity of BFP expres-
sion that was regulated by Tat and the LTR promoter. A representative
FACS histogram analysis demonstrated the expression of LTR-Tat-BFP
at MOI of 4 in control HeLa cells (black line) or HeLa–HA-CycT1-U7
cells (gray line) and conﬁrmed the aforementioned results (Fig. 2C).
To demonstrate that the inhibitory effects of stably-expressed HA-
CycT1-U7 were speciﬁc to the HIV-LTR promoter and Tat, HeLa–HA-
CycT1-U7 cells or control cells were transduced with increasing MOI
values of VSV-G pseudotyped lentivirus that expressed the BFP re-
porter gene under the control of the Tat-independent CMV promoter.
48 h post transduction, BFP expression in transduced cells was mea-
sured by FACS (Fig. 2D). Transcription of the CMV-BFP lentivirus
was not affected by stable expression of HA-CycT1-U7. In bothFig. 3. Interactions of HA-CycT1-U7 with HIV Tat Cdk9 and HEXIM1(A) HA-CycT1-U7 binds
empty plasmid (lane 2). HeLa cells that did not express HA-CycT1-U7 were also transfected
control plasmid (lane 4). 48 h post transfection cells were harvested and lysed. Cell lysates w
before subjected to SDS-PAGE and western blot with anti-myc antibody for the detection of
CycT1-U7 total cell lysate. Lower panel represents HA-CycT1 protein levels in the IP reaction
input of HA-Cyclin T1-U7 in 10% of HeLa–HA-CycT1-U7 total cell lysate. Lane 2 — HA-CycT1
HEXIM1 — HeLa–HA-CycT1-U7 stable cells or control HeLa cells that did not express HA-Cy
empty plasmid. 48 h post transfection, cells were lysed and cell lysates were incubated with
were subjected to SDS-PAGE and western blot analysis to detect endogenous Cdk9 or HEXIM
HA-CycT1-U7 (lanes 5 and 6) and HA-CycT1 (1–280) (lanes 5 and 7) in the IP reactions was
endogenous Cdk9 or HEXIM1 in 10% of total cell lysate (lanes 1–4). Additionally, input expre
3) were also conﬁrmed by anti-HA western blotting.HeLa–HA-CycT1-U7 stable cells and control HeLa cells that did not ex-
press HA-CycT1-U7, transduction was highly efﬁcient (not shown)
and similar values of geomean of transduction were obtained at dif-
ferent values of viral MOI, conﬁrming similar transcription efﬁcien-
cies of the CMV-BFP lentivirus in both cell types (Fig. 2D).
Stably expressed CycT1-U7 interacts with HIV-Tat in cells
Next, in order to better understand the molecular mechanism by
which stably expressed HA-CycT1-U7 blocks HIV transcription, bind-
ing between stably expressed HA-CycT1-U7 and transiently
expressed Tat was analyzed in HeLa–HA-CycT1-U7 cells or HeLa
cells that did not express HA-CycT1-U7. The cells were transfected
with HIV-1 myc-Tat and 48 h post transfection, cells were lysed and
immunoprecipitated (IP) with anti-HA antibody. Western blot analy-
sis with an anti-myc antibody to detect myc-Tat in the precipitateTat — HeLa–HA-CycT1-U7 stable cells were transfected with myc-Tat and HA-pCDNA3
with myc-Tat and either human HA-CycT1 (1–280) (lane 3) or an empty HA-pCDNA3
ere incubated with an anti-HA antibody and immunoprecipitated with protein A beads,
myc-Tat. Lane 1 represents the input of myc-Tat protein expression in 10% of HeLa–HA-
s as measured by western blot analysis with an anti-HA antibody. Lane 1 lower panel —
-U7. Lane 3 — expression of HA-CycT1 (1–280).(B) HA-CycT1-U7 fails to bind Cdk9 or
cT1-U7 were transfected with human HA-CycT1 (1–280) or with control HA-pCDNA3
an anti-HA antibody before immunoprecipitated (IP) with protein A beads. IP reactions
1 using the appropriate antibodies (right panels; lanes 5–8; IP: anti HA). Expression of
also conﬁrmed. Left panel represents western blot analysis of input expression levels of
ssion levels of HA-CycT1-U7 (lanes 1 and 2) and human HA-CycT1 (1–280) (lanes 1 and
156 A. Kuzmina et al. / Virology 152 (2012) 152–161indicated that HA-CycT1-U7 efﬁciently bound to Tat (Fig. 3A, lane 2).
Importantly, Tat expression levels were not modulated by stably
expressed HA-CycT1-U7 (Fig. 3A: lane 1 — input upper panel). As
expected, in control cells that did not express HA-CycT1-U7, tran-
siently expressed human CycT1 containing only the N-terminal 280
residues (HA-CycT1 1–280) also bound Tat (Fig. 3A; lane 3). Control
cells that expressed HA-pCDNA3 empty plasmid did not bind Tat,
conﬁrming the speciﬁcity of the IP reaction (Fig. 3A; lane 4). Levels
of HA-CycT1-U7 (Fig. 3A; lane 2) and wild-type human HA-CycT1
(1–280) (Fig. 3A; lane 3) in the IP were also monitored using anti-
HA antibody (Fig. 3A; lower panel). We conclude that stably
expressed HA-CycT1-U7 binds to Tat in cells.
CycT1-U7 does not bind Cdk9 or HEXIM1
Since HIV gene transcription was inhibited in HeLa–HA-CycT1-U7
stable cells despite high expression levels of HA-CycT1-U7 and Tat, an
alternative mechanism for the inhibitory effects of HA-CycT1-U7 on
viral transcription was investigated. Interactions between HA-
CycT1-U7 and endogenous Cdk9 or HEXIM1 were analyzed in HeLa–
HA-CycT1-U7 stable cells (Fig. 3B). As positive control, the binding
of wild-type human CycT1 (1–280) to Cdk9 or HEXIM1were also ver-
iﬁed. HeLa–Ha-CycT1-U7 stable cells or control cells that did not ex-
press HA-CycT1-U7 were transfected with either HA-CycT1 (1–280)
(Fig. 3B; lanes 5 and 7), or HA-pCDNA3 empty vector (Fig. 3B; lanes
6 and 8). 48 h post transfection, cells were lysed and lysates were pre-
cipitated with an HA antibody (IP: α-HA), followed by western blot
analysis with antibodies that detected either endogenous Cdk9 or
HEXIM1 (Fig. 3B; lanes 5–8). In HeLa–HA-CycT1-U7 stable cells, HA-
CycT1-U7 failed to bind Cdk9 and HEXIM1 (Fig. 3B; lane 6). In these
cells, transiently expressed wild-type human HA-CycT1 (1–280) efﬁ-
ciently bound to Cdk9 (Fig. 3B; lane 5; anti-Cdk9 western blot) and
HEXIM1 (Fig.3B; lane 5; anti-HEXIM1 western blot). These results
conﬁrmed that HA-CycT1-U7 stable expression did not disrupt en-
dogenous P-TEFb complex formation. Human HA-CycT1 (1–280)
also bound to Cdk9 or HEXIM1 in HeLa cells that did not express
HA-CycT1-U7, conﬁrming interactions between wild-type cyclin T1
(1–280) and endogenous Cdk9 or HEXIM1 (Fig. 3B; lane 7). Expres-
sion of HA-CycT1-U7 (lanes 5 and 6) and of HA-CycT1 (1–280)
(lane 7) in the IP reactions was also conﬁrmed by western blot with
anti-HA antibody (lower panel). Input expression levels of endoge-
nous Cdk9 or HEXIM1 in both HeLa–HA-CycT1-U7 and HeLa control
cells lysates were also monitored (Fig. 3B; lanes 1–4). Input expres-
sion levels of human HA-CycT1 (1–280) (lane 3) and HA-CycT1-U7
(lane 2) were veriﬁed by anti-HA western blot. As both HA-CycT1-
U7 and HA-CycT1 (1–280) were detected by an anti HA western
blot, lane 1 represented the expression of both HA-CycT1-U7 and
HA-CycT1 (1–280) in HeLa HA-CycT1-U7 stable cells, while lane 3
showed input expression of only HA-CycT1 (1–280) in HeLa cells.
We conclude that HA-CycT1-U7 did not bind Cdk9 or HEXIM1. Impor-
tantly, over-expressed HA-CycT1-U7 did not disrupt interactions be-
tween endogenous P-TEFb subunits and between P-TEFb and
HEXIM1.
CycT1-U7 does not disrupt cellular P-TEFb-mediated transcription
To verify that HA-CycT1-U7 does not disrupt the transcription ac-
tivity of endogenous P-TEFb, activation of transcription via the myo-
cyte enhancer factor 2 (MEF2C) or via NFkB were tested in the
presence of HA-CycT1-U7 expression (Figs. 4A and B, respectively).
P-TEFb was previously reported to stimulate transcription via both
DNA-bound transactivators (Barboric et al., 2001; Nojima et al.,
2008). Initially, a reporter plasmid that expressed the luciferase
gene under the control of the MEF2-dependent muscle creatine ki-
nase (MCK) promoter was co-transfected into HeLa cells together
with MEF2C transactivator and increasing concentrations of HA-CycT1-U7 lentivector (Fig. 4A; lanes 2–6). 48 h post transfection,
MEF2C-dependent luciferase activity was measured and compared
to HeLa cells that were co-transfected with an empty lentivector,
thus did not express HA-CycT1-U7 (lane 3). MEF2C activated the
MCK-Luc promoter by 3 fold (lane 3). Importantly, increasing expres-
sion of HA-CycT1-U7 had no effect on the MEF2C mediated transacti-
vation of the MCK-luc promoter (Fig. 4A; lanes 4–6). Transient co-
expression of HA-CycT1-U7 with either wild type human CycT1
(1–280) (Fig. 4A; lane 7) or Cdk9 and wild-type human CycT1
(1–280) (Fig. 4A; lane 8) led to an additional increase of MEF2C me-
diated transactivation. Western blot analysis with the indicated anti-
bodies conﬁrmed the expression of HA-CycT1-U7 (Fig. 4A; lanes 4–8),
HA-CycT1 (1–280) (Fig. 4A; lanes 7 and 8), FLAG-Cdk9 (Fig. 4A; lane
8), or FLAG-MEF2C (Fig. 4A; lower panels). We conclude that HA-
CycT1-U7 did not interfere with the ability of P-TEFb to stimulate
MEF2C mediated transcription.
The activity of NFkB promoter harboring luciferase reporter gene
was also monitored in HeLa–HA-CycT1-U7 stable cells (white bars)
and compared to the promoter activity in control HeLa cells that did
not express HA-CycT1-U7 (black bars) (Fig. 4B). As shown, in HeLa–
HA-CycT1-U7 stable cells or control HeLa cells, expression of human
HA-CycT1 (1–280) activated the NFkB-luciferase reporter 3-fold above
basal transcription levels where no CycT1 (1–280) was added (Fig. 4B;
compare lanes 2 and 3). Similarly, expression of Cdk9 stimulated
NFkB transactivation in both cell types (2-fold above basal levels of ac-
tivation; Fig. 4B; lane 4). Co-expression of Cdk9 and CycT1 (1–280) in
both HeLa–HA-CycT1-U7 stable cells and in control HeLa cells that did
not express HA-CycT1-U7, led to a signiﬁcant increase of NFkB-
mediated transactivation, up to 8-fold above basal transcription levels
(Fig. 4B; lane 5). As a positive control for the activation of NFkB, treat-
ment of both cell types with TNFα efﬁciently activated the promoter,
leading to 12-fold induction of NFkB activity (Fig. 4B; lane 6). Western
blot analysis conﬁrmed the expression of HA-CycT1-U7 in HeLa–HA-
CycT1-U7 stable cells, HA-CycT1 in HeLa cells (1–280) (Fig. 4B; lanes 3
and 5), FLAG-Cdk9 (Fig. 4B; lanes 4 and 5) and β-actin for similar pro-
tein levels that were loaded on the gel (Fig. 4B; lower panel). Overall,
CycT1-U7 did not interfere with the ability of endogenous P-TEFb to
stimulate NFkB-mediated transcription.
CycT1-U7 inhibits HIV transcription in a T cell line
HA-CycT1-U7 was also stably expressed in a human T
lymphoblast-like cell line (CEMX174; CEM). CEM–HA-CycT1-U7 sta-
ble cells were generated as described earlier, using lentiviruses that
expressed HA-CycT1-U7 under the regulation of the CMV promoter.
The expression of HA-CycT1-U7 in CEM cells was veriﬁed by western
blot, using anti-HA antibody (Fig. 5A; compare lanes 1 and 2). To test
inhibitory effects of CycT1-U7 on HIV transcription, CEM–HA-CycT1-
U7 were transduced at different MOIs with VSV-G pseudotyped
HIV-LTR-Tat-BFP lentivirus that expressed a BFP reporter gene
under the regulation of the HIV-LTR and Tat (Figs. 5B and C). Viral
stock was generated in 293 T and its titer was determined by trans-
ducing 293 T cells and analyzing their BFP expression 48 h post trans-
duction by FACS. LTR-Tat-BFP lentivirus titer was calculated as
1×107/ml (see Materials and methods). Transduced CEM–HA-
CycT1-U7 stable cells were harvested 72 h post transduction and sub-
jected to FACS analysis to measure the expression of BFP. As shown,
BFP expression in CEM–HA-CycT1-U7 was substantially lower
(Figs. 5B and C; white bars) than in control CEM cells that did not ex-
press HA-CycT1-U7 (Figs. 5B and C; black bars). This inhibition was
observed in all MOI tested, although signiﬁcantly more in lower
MOI values. Inhibition of viral transcription was detected in the geo-
mean values of transduction (Fig. 5B), while percentage of cells that
were transduced with HIV-LTR-BFP were similar in both CEM–HA-
CycT1-U7 and control CEM cells (Fig. 5C). This conﬁrmed that trans-
duction efﬁciencies with the HIV-LTR-Tat-BFP lentivirus were similar
Fig. 4. CycT1-U7 does not interfere with the activity of endogenous P-TEFb to stimulate transcription by MEF2C or NFkB activators(A) CycT1-U7 does not disrupt MEF2C dependent
transcription — HeLa cells were co-transfected with the MCK-luciferase promoter containing two MEF2 binding sites (lanes 2–8; 0.1 μg) and with FLAG-MEF2C (0.2 μg; lanes 3–8),
as well as with increasing amounts of HA-CycT1-U7 (lanes 4–6; 0.4; 0.8; 1.2 μg). Additionally, HA-CycT1-U7 (0.8 μg) was also co-expressed with wild-type human HA-CycT1
(1–280) (0.8 μg; lane 7) or with human HA-CycT1 (1–280) and FLAG-Cdk9 (0.8 μg and 1 μg respectively; lane 8). 48 h post transfection, cells were lysed and their luciferase activity
was measured. Lower panel represents western blot analysis of HA-CycT1-U7 (lanes 4–8), as well as of HA-CycT1 (1–280) (lanes 7 and 8), FLAG-Cdk9 (lane 8), FLAG-MEF2C (lanes
3–8). β-actin expression levels were also monitored to control proteins amounts that were loaded on the protein gel. Luciferase activity is presented as fold of transactivation, rel-
ative to the basal activity of the MCK-Luc promoter without NEF2C (lane 2). Luciferase activity of non-transfected cells is also presented in lane 1. Data are the representative of
three independent experiments.(B) CycT1-U7 does not disrupt NFkB mediated transcription — HeLa–HA-CycT1-U7 stable cells (white bars) and control cells that did not express
HA-CycT1-U7 (black bars) were transfected with an NFkB-luciferase reporter plasmid (0.2 μg; lane 2) and either HA-CycT1 (1–280) (0.6 μg; lane 3) or FLAG-Cdk9 (0.6 μg; lane 4)
expression plasmids. Cells were also co-transfected with human HA-CycT1 (1–280) and FLAG-Cdk9 expression plasmids (0.6 μg of each; lane 5). 48 h post transfection cells were
lysed and their luciferase activity was determined. As a positive control for NFkB promoter activity, cells were treated for 8 h with TNFα (10ng/ml; lane 6) before analyzed for their
luciferase activity . Lower panel represents western blot analysis of stably expressed HA-CycT1-U7 (lanes 1–6; in HeLa–HA-CycT1-U7), as well as HA-CycT1 (1–280) (lanes 3 and 5;
analyzed in HeLa cells only) and FLAG-Cdk9 (lane 4 and 5) proteins. β-actin expression levels were also monitored to control amounts of proteins that were loaded on the SDS-
PAGE gel. Luciferase activity is presented as fold of transactivation, relative to the basal activity of the NFkB-Luc promoter transfected alone (lane 2). The luciferase background
activity in non-transfected cells is also presented in lane 1. Data are the representative of three independent experiments.
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level of Tat-dependent transcription (Figs. 5B and C). A representative
FACS analysis histogram at an MOI of 4 conﬁrmed the aforemen-
tioned results (Fig. 5D). Signiﬁcantly, the inhibitory effects of HA-
CycT1-U7 in CEMX174 T cells were speciﬁc to the HIV-LTR, as HIV
transcription of a lentivirus bearing the BFP reporter gene under the
regulation of the CMV promoter (HIV-1-CMV-BFP) was not inhibited
in stable CEM–HA-CycT1-U7 T cells (Fig. 5E). We conclude that
CycT1-U7 also inhibits HIV transcription in T cells.
Inhibition of HIV transcription in primary CD4+ cells that stably express
HA-CycT1-U7
The ability of CycT1-U7 to inhibit HIV transcription was also ana-
lyzed in human CD4+ primary T cells that stably expressed HA-
CycT1-U7. CD4+ T primary cells were isolated from PBMCs and stim-
ulated for 3 days with CD3/CD28 T cell expander beads, supplemented
with IL-2. Activated cells were then transducedwith lentivirus expres-
sing CMV-HA-CycT1-U7 and cells were further propagated for another
three days. Copy number of integrated HA-CycT1-U7 gene in primary
CD4+ transduced cells was conﬁrmed by real time PCR, using primers
located on the lentiviral vector. Initially, a standard curvewas generat-
ed by real time PCR, where Ct values were plotted against increasing
copy numbers of the HA-CycT1-U7 lentivector that were supplemen-
ted with 200 ng of genomic DNA (corresponding to 33,000 cells).200 ng of genomic DNA was also extracted from CD4+ cells that
were transduced with HA-CycT1-U7 lentivirus. Copy number of the
integrated HA-CycT1-U7 gene in CD4+ cells was determined based
on the standard curve. Analysis of genomic DNA extracted from HA-
CycT1-U7 transduced CD4+ cells resulted in a Ct value of 25, which
corresponded to 31,662 copies/200 ng DNA. Overall, HA-CycT1-U7
gene marking in CD4+ transduced cells was calculated at an average
of one copy/cell. To analyze the effect of stably expressed HA-CycT1-
U7 on HIV transcription in CD4+ primary cells, control or CD4+
−HA-CycT1-U7 stable cells were challenged with HIVNL4.3 infectious
clone at increasing MOIs. Viral titer of the HIV-1NL4.3 infectious clone
was approximately 1×107/ml as determined by transducing HeLa-
TZM-bl reporter cells. 96 h post infection, supernatant-containing
virus was collected and HIV-p24 expression levels were determined
by ELISA. MOI-dependent inhibition of HIV viral production was ob-
served in CD4+ cells that stably expressed HA-CycT1-U7. At MO1 of
0.01, viral production in these cells was 70% lower than viral produc-
tion in CD4+ control cells that did not express HA-CycT1-U7
(Fig. 6). We conclude that stably expressed CycT1-U7 inhibits HIV
transcription in primary CD4+ cells.
Discussion
In this study, a CycT1 mutant, cyclin T1-U7, consisting of N-
terminal mutation in the cyclin box, was characterized for
Fig. 5. Stably expressed HA-CycT1-U7 inhibits HIV-LTR-Tat transcription in CEMX174 T cells lines(A) HA-CycT1-U7 stable expression in CEMX174 — CEMX174 T cells were trans-
duced with lentiuvirus that expressed HA-CycT1-U7 to generate CEM–HA-CycT1-U7. 48 h post transduction cells were subjected to puromycin selection. HA-CycT1-U7 expression
was validated by western blot of transduced cells using anti-HA antibody. CEM–HA-CycT1-U7 stable T cells (lane 2) and control cells that did not express HA-CycT1-U7 (lane 1)
were harvested, analyzed on SDS-PAGE and subjected to anti-HA western blot.(B, C) HA-CycT1-U7 inhibits gene transcription of LTR-Tat-BFP lentivirus in CEMX174 T (CEM)
cells — CEM–HA-CycT1-U7 stable T cell lines (white bars) or control CEM T cells that did not express HA-CycT1-U7 (black bars) were transduced with decreasing MOI of VSV-G
pseudotyped HIV-LTR-Tat-BFP lentivirus. 48 h post transduction cells were harvested and analyzed for BFP expression by FACS. Panel (B) represents geomean values, while
panel (C) is the percentage of infection in stable and control cells, conﬁrming high and equal efﬁciencies of transduction in both CEM and CEM–HA-CycT1-U7 cells. Results are
the representative of three independent assays and error bars represent standard derivation.(D) FACS analysis histograms of CEMX174 stably expressing HA-CycT1-U7 — CEM–
HA-CycT1-U7 stable cells (gray line) or CEM cells that did not express HA-CycT1-U7 (black line) were transduced with the HIV-LTR-Tat-BFP lentivirus. 48 h post transduction,
cells were analyzed by FACS for their BFP expression. Presented is a representative histogram of transduction at MOI of 4. Similar plots were obtained following transduction of
cells at different MOI.(E) Stably expressed HA-CycT1-U7 in CEMX174 T cells does not inhibit gene transcription of CMV-BFP lentivirus — CEM–HA-CycT1-U7 stable cells (white
bars) or CEM cells that did not express HA-CycT1-U7 (black bars) were transduced with decreasing MOI of VSV-G pseudotyped HIV-CMV-BFP lentivirus. BFP expression was mea-
sured by FACS 48 h post transduction. Results of geomean values are the representative of three independent assays and error bars represent standard derivation.
Fig. 6. CycT1-U7 inhibits HIV transcription in human CD4+ primary T cells Human
CD4+ T cells were isolated from PBMCs and stimulated for 3 days with CD3/CD28 T
cell expander beads, supplemented with IL-2. Activated cells were transduced with
lentivirus expressing HA-CycT1-U7 and cells and were propagated for another 3 days.
Gene marking analysis to determine copy number of integrated HA-CycT1-U7 gene was
performed by real time PCR, analyzing 200 ng of total genomic DNA that was extracted
from transduced CD4+ cells that stably expressed HA-CycT1-U7 (see Materials and
methods for details). Human CD4+ T cells that stably expressed HA-CycT1-U7 (white
bars) or control CD4+ cells that did not express HA-CycT1-U7 (black bars) were infected
with decreasing MOIs of HIV-1NL4.3 infectious clone. MOI values were determined by
infecting TZM-bl indicator cells andmeasuring their β-gal activity. 96 h post transduction,
supernatant from CD4+ cells that expressed HA-CycT1-U7 was collected and viral p24
expression levels were measured by p24 ELISA.
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on HIV transcription were tested in cells. Initially, HA-CycT1-U7 was
stably expressed in HeLa cells and HeLa–HA-CycT1-U7 cells were
generated. In these cells, HA-CycT1-U7 expression levels were high
and but did not modulate the expression levels of Tat (Fig. 1). Impor-
tantly, HA-CycT1-U7 had no toxic effects on HeLa–HA-CycT1-U7 cells,
which remained healthy throughout all experiments. The transcrip-
tion of an LTR-Tat-BFP lentivirus was efﬁciently inhibited in HeLa-
HA-CycT1-U7 stable cells (Fig. 2). This inhibition was speciﬁc to the
HIV LTR promoter and to Tat, as lentiviral transcription of a BFP re-
porter gene driven by the CMV promoter (CMV-BFP), or of a reporter
luciferase gene expression stimulated by two previously reported P-
TEFb-dependent transactivators (NFkB and MEF2C) were not dis-
rupted by HA-CycT1-U7 (Figs. 2 and 4) (Barboric et al., 2001;
Nojima et al., 2008). Inhibition of HIV transcription was measured
only in the geomean BFP intensity values, while the efﬁciency of
viral infection, as analyzed by the percentage of BFP expressing
cells, was similar in both HeLa-HA-CycT1-U7 stable cells and HeLa
cells that did not express HA-CycT1-U7. This conﬁrmed that inhibi-
tion of viral transcription by CycT1-U7 was Tat-dependent at the
step of gene transcription from the LTR. Nevertheless, despite high
expression levels of both Tat and HA-CycT1-U7, HIV transcription
was not rescued in HeLa–HA-CycT1-U7 cells (Fig. 2). Similarly, stably
expressed HA-CycT1-U7 also inhibited HIV transcription in a
CEMX174 T cell line and in primary CD4+ PBMC, which are more
physiologically relevant to HIV infection (Figs. 5 and 6). Stable ex-
pression of HA-CycT1-U7 in transduced CD4+ cells led to 70%
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cells that did not express HA-CycT1-U7 (Fig. 6). As in HeLa–HA-
CycT1-U7 cells, over expression of HA-CycT1-U7 had no toxic effects
in CEMX174 or CD4+ primary cells. The observations that stably
expressed HA-CycT1-U7 and Tat maintained high expression levels
in cells and yet HIV transcription was efﬁciently inhibited were sur-
prising in light of our previous study on the CycT1-U7, which demon-
strated low expression levels of both CycT1-U7 and Tat when
transiently over-expressed. Low steady-state expression levels of
CycT1-U7 efﬁciently inhibited HIV transcription by promoting the
degradation of Tat (Jadlowsky et al., 2008). However, this previous
study also showed that HIV transcription was not fully restored fol-
lowing treatment of cells with proteasome inhibitors, which did ele-
vate CycT1-U7 and Tat protein expression levels. Thus, additional
mechanisms for CycT1-U7 mediated inhibition of HIV transcription
may exist. Data presented herein support this hypothesis, as high ex-
pression levels of stably expressed CycT1-U7 and of Tat still could not
rescue the inhibition of HIV transcription in HeLa–HA-CycT1-U7 cells.
Indeed, analysis of the interactions between CycT1-U7, Tat, Cdk9 and
HEXIM1 revealed that stably expressed HA-CycT1-U7 bound to Tat,
but failed to interact with Cdk9 or HEXIM1 in cells. Thus, CycT1-U7 rep-
resents a novel CycT1 mutant that sequesters Tat from P-TEFb, leading
to inhibition of HIV gene transcription.Mutations in CycT1-U7 arewith-
in the N-terminus residues of the cyclin box, where Cdk9 binds to
CycT1, providing an explanation for the inability of HA-CycT1-U7 to
bind Cdk9 (Anand et al., 2008; Baumli et al., 2008). Importantly in the
current study, we further demonstrated that this region is also impor-
tant for binding between CycT1 and HEXIM1 and presumably cooper-
ates with the TRM region (residues 255–270) in CycT1, which was
previously reported to bind Tat, TAR (Garber et al., 1998) and HEXIM1
(Michels et al., 2003, 2004; Schulte et al., 2005; Yik et al., 2003, 2004).
TRM also forms a hydrophobic joint pocket with N-terminal residues
in cyclin T1 that have been recently reported to mediate Tat binding
and transactivation (Asamitsu et al., 2011). The study herein shows
that this N-terminal region in the cyclin box might also be involved in
binding to HEXIM1, supporting the model of competition between
HEXIM1 and Tat on Cyclin T1 binding (Schulte et al., 2005). The joint
surface also accommodates binding of CycT1 to TAR or 7SK snRNA, im-
plying a role for N-terminal residues in mediating binding between
CycT1 and its RNA targets. CycT1-U7 mutations and in additional
N-terminalmutations in the cyclin box of human cyclin T1 are currently
being analyzed for involvement in binding to HEXIM1. In this context,
alignment of human CycT1 proteins with CycT1 from other hosts
(equine and canine) should contribute to the identiﬁcation of additional
residues that may be important for Tat and HEXIM1 binding. We have
previously reported that a leucine 29 in equine cyclin T1, which is a va-
line in human cyclin T1, is important for promoting the assembly of
equine cyclin T1 and Tat on equine TAR and support equine Tat transac-
tivation. It will be interesting to validate the importance of V29 residue
in binding of human cyclin T1 to HEXIM1, as it is located in the cyclin
box, at close proximity to the CycT1-U7 mutations (Taube et al.,
2000). Furthermore, interactions between CycT1-U7 and its RNA targets
are also being veriﬁed. CycT1-U7binds to Tat, thus, it should promote its
assembly on TAR. However, we demonstrated that CycT1-U7 does not
bind Cdk9, which was reported to facilitate the formation of a high af-
ﬁnity Tat-TAR-P-TEFb tripartite complex (Garber et al., 2000). Further-
more, as CycT1-U7 does not bind to HEXIM1, it may not support
interactions between P-TEFb and 7SK snRNA. In this scenario, HEXIM1
and 7SK snRNA will not be misrouted to a non-functional P-TEFb. In
contrast, as some reports show that P-TEFb binds 7SK snRNA indepen-
dently of HEXIM1, CycT1-U7 might bind 7SK snRNA and misguide it
to a non-functional large complex, which can also include HEXIM1
(Li et al., 2005; Yik et al., 2003). Another possibility might be that HA-
CycT1-U7 will have a higher afﬁnity to 7SK snRNA, but not to TAR,
resulting in sequestering P-TEFb to the large transcriptionally inactive
complex.Moreover, as binding between CycT1 and HEXIM1 requires the
phosphorylation of a conserved Thr186 residue in the T-loop of
Cdk9, our results conﬁrm that failure of HA-CycT1-U7 to bind
HEXIM1 might also be due to its inability to bind Cdk9 (Chen et al.,
2004; Li et al., 2005). Overall, it is still to be determined whether
these residues in the cyclin box of CycT1 are directly involved in bind-
ing to HEXIM1, or it is the Cdk9 binding and phosphorylation that are
essential for interactions between CycT1, Cdk9 and HEXIM1. A de-
tailed single point mutations analysis in this region is currently
undergoing.
To further use CycT1-U7 in vivo as an antiviral regimen, it was es-
sential to conﬁrm that HA-CycT1-U7 did not affect cell viability and
not disrupt global cell transcription. Indeed HA-CycT1-U7 stable ex-
pression had no side effects or any cell toxicity, inhibition of cell pro-
liferation, or growth arrest. Moreover, HA-CycT1-U7 stable
expression did not interfere with the binding between human
CycT1 and endogenous HEXIM1 or Cdk9 (Fig. 3B) and also did not in-
terfere with P-TEFb-mediated transcription of MEF2C or NFkB activa-
tors (Fig. 4).
Since CycT1-U7 speciﬁcally functions via binding to Tat, it could
inhibit HIV transcription in both acutely infected cells and reactivated
latently infected cells. The inhibitory effects of CycT1-U7 in various la-
tent HIV models are currently being tested. Future studies with a sys-
tematic mutational analysis should lead to a better understanding of
P-TEFb mediated HIV and eukaryotic transcription, as well as to the
development of safer and effective anti-HIV agents that can be used
regardless of the stage of HIV infection.
Materials and methods
Plasmids
For stable CycT1-U7 expression, a lentiviral vector expressing HA-
CycT1-U7 under the control of the CMV promoter was used. It also
expressed puromycin via IRES sequence. For analysis of inhibition of
lentiviral gene transcription, a lentiviral vector expressing the Blue
Florescence Protein (BFP) reporter, regulated either by HIV-LTR-Tat
(HIV-LTR-BFP) or the CMV promoter (HIV-CMV-BFP) was used to
generate recombinant lentivirus. pCDNA3-HA-CycT1 (1–280) coded
for human CycT1 containing N-terminal 1–280 residues. pCDNA3-
myc Tat expressed Tat 101, while the pCDNA3-HA-Tat coded a
shorter Tat-86 version. pCDNA3-Flag-Cdk9 coded for human Cdk9
under the regulation of the CMV promoter. MEF2C expression plas-
mid pCMX-1F-MEF2C and the reporter plasmid pGL2-MEF2-Luc
(MCK-Luc) coded for the rat MCK promoter-driven ﬁreﬂy -luciferase
(MCK-Luc) reporter gene that contains two MEF2 binding sites and
were reported previously (Nojima et al., 2008). pNFkB-Luc contained
the ﬁreﬂy luciferase genedriven by four copies of the NFkB response
element located upstream of the minimal TATA promoter.
Cell lines
HEK293T and HeLa cells were maintained in DMEM containing
10% FCS, at 37 °C with 5% CO2. Human CEMX174 and CD4+ primary
cells were maintained in RPMI-1640 media supplemented with 10%
FCS.
Production of HIV lentiviruses
VSV-G pseudotyped single round HIV particles were produced by
co-transfection of the lentiviral vector, HIV gag/pol, pRev, pTat and
VSV-G into 293 T by calcium phosphate. 48 h post transfection, super-
natant was harvested and ﬁltered through 0.45 μ ﬁlter. Lentiviral par-
ticles were concentrated by ultracentrifugation for 2.5 h at 25 K rpm
and the pellet was re-suspended in cold PBS. Lentiviral titer was cal-
culated by infection of 293 T cells and measuring BFP expression in
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reached 1×107/ml. Infectious HIV was also produced in HEK293T
by transfecting HIV-1NL4-3. 48 h post transfection supernatant was
collected and viral titer was measured by transducing TZM-bl indica-
tor cells. 48 h post infection cells were harvested and their β-
galactosidase activity was measured.
Generation of HeLa–HA-CycT1-U7 stable cell lines
HeLa cells were transduced for 4 h with concentrated lentivirus
that expressed the CMV-HA-CycT1-U7. Cells were then subjected to
selection with 10 μg/ml puromycin for generating HeLa–HA-CycT1-
U7 stable cells. In the case of CEMX174 T cells, 1 μg/ml puromycin
was used. Seven days post transduction the drug was removed and
cells were maintained in DMEM supplemented with 10% FCS media.
HA-CycT1-U7 expression was veriﬁed by western blot using anti-HA
monoclonal antibody (SIGMA). Control HeLa cells that did not ex-
press HA-CycT1-U7 were transduced with an empty lentivirus that
did not express HA-CycT1-U7 but were selected by puromycin.
Determination of viral infectivity
Control HeLa cells or HeLa–HA-CycT1-U7 stable cells were trans-
duced for 4 h at different MOIs of the indicated lentiviruses. 48 h
post transduction cells were ﬁxed with 2% paraformaldehyde and an-
alyzed by FACS for BFP expression.
Immunoprecipitation
Control or HeLa–HA-CycT1-U7 stable cells were transfected with
the indicated DNA with lipofectamine 2000 (Invitrogen). 48 h post
transfection, cells were lysed with hypotonic lysis buffer (20 mM
Tris pH 7.5, 5 mM. MgCl2, 5 mM CaCl2, 1 mM DTT, 1 mM EDTA, pro-
tease inhibitor cocktail from Sigma) and lysates were further incubat-
ed with the indicated antibodies. Lysates were incubated with protein
A-sepharose beads at 4 °C for 8 h and the beads were washed exten-
sively with washing buffer. Precipitated proteins were separated on
SDS-PAGE and analyzed by western blotting with the indicated spe-
ciﬁc antibodies.
Luciferase reporter assays
Cells were co-transfected with the indicated luciferase reporter
plasmid and effector plasmid using lipofectamine 2000. 48 h post
transfection, cells were harvested and their luciferase activity was
measured according to the manufacture manual (Promega).
Transduction of CD4+ primary cells and infection with HIV
Human CD4+ cells were isolated from human PBMCs using CD4+
T cells isolation kit (RosetteSep), followed by centrifugation via den-
sity gradient medium. CD4+ T cells were stimulated with CD3/
CD28 beads for 48 h and then transduced with HA-CycT1-U7 expres-
sing lentivirus. 48 h post transduction, cells were infected with HIV-
1NL4-3 at MOI of 0.01–1. Viral production was quantiﬁed by ELISA as
relative amount of HIV Gag-p24 in supernatant.
Real time PCR analysis for HA-CycT1-U7 marking in CD4+ primary cells
Total genomic DNA from CD4+ primary transduced cells that sta-
bly expressed HA-CycT1-U7 was extracted using ReliaPrep Blood sys-
tem (Promega). 200 ng of total DNA was then analyzed by real time
PCR, using primers located on the CMV promoter and on HA-CycT1-
U7. PCR conditions were as follows: 98 °C for 30 s; 72 °C for 1 min
for c40 cycles. To determine CycT1-U7 copy number, a standard
curve was generated where increasing copy numbers of the HA-CycT1-U7 lentivector plasmid were diluted in 200 ng of genomic
DNA, and were analyzed by real-time PCR. A standard curve was gen-
erated were Ct values were plotted against HA-CycT1-U7 copy num-
ber. PCR end products were also analyzed on an agarose gel to
verify the speciﬁcity of the HA-CycT1-U7 expression and were pre-
sented as a 250 bp band. The sequences of the PCR primers will be
provided upon request.Acknowledgments
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